ERBB2 and triple-negative breast carcinoma: Increased survival in ER+/HER2+ breast cancer patients [44, 45] and triple-negative breast cancer [46] treated with the anti-diabetic drug metformin have been reported, as well as investigations regarding its ability to increase survival in other forms of malignancy [47].